MDxHealth SA (MDXH) vs Personalis (PSNL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Personalis (PSNL) has outperformed MDxHealth SA (MDXH) over the past year, gaining 85.0% versus a loss of 87.2%. Personalis is the larger company by market cap ($1.72 billion vs $55.4 million), about 31.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXH | PSNL |
|---|---|---|
| Share price | $0.5805 | $16.06 |
| Market cap | $55.39M | $1.72B |
| 1-day change | -3.22% | +0.37% |
| YTD return | -83.74% | +101.76% |
| 1-year return | -87.16% | +85.02% |
| 5-year return | — | -19.46% |
| EPS (TTM) | $-0.70 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.33 | $18.89 |
| 52-week low | $0.40 | $4.96 |
| Distance from 52-week high | -89.11% | -14.98% |
| Analyst consensus | none | hold |
| Avg. price target upside | +210.08% | -5.54% |
| Average volume | 5.69M | 3.59M |
| Shares outstanding | 95.42M | 106.80M |
| Employees | 364 | 259 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Personalis is about 31.0 times larger than MDxHealth SA by market value ($1.72B vs $55.39M).
- PSNL has outperformed MDXH by 172.2 percentage points over the past year.
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Healthcare · Diagnostics & Research · 364 employees
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Healthcare · Diagnostics & Research · 259 employees
MDXH vs PSNL FAQ
Which is bigger, MDxHealth SA or Personalis?
Personalis (PSNL) is larger, with a market capitalization of $1.72B compared with $55.39M for MDxHealth SA (MDXH).
Which stock has performed better over the past year, MDXH or PSNL?
PSNL returned +85.02% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are MDxHealth SA and Personalis in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.